(in thousands)
Three months ended Nine months ended
------------------------ ------------------------
September September September September
30, 30, 30, 30,
2024 2023 2024 2023
----------- ----------- ----------- -----------
Operating
expenses $ 20,073 $ 26,827 $ 74,507 $ 87,914
Impairment -- -- (2,971) --
Restructuring (1,690) -- (3,087) --
------ ------- ------ -------
Non-GAAP
operating
expenses $ 18,383 $ 26,827 $ 68,449 $ 87,914
====== ======= ====== =======
AKOYA BIOSCIENCES, INC. AND SUBSIDIARY
Loss From Operations to Non-GAAP Loss From Operations Reconciliation (unaudited)
(in thousands)
Three months ended Nine months ended
---------------------- ----------------------
September September September September
30, 30, 30, 30,
2024 2023 2024 2023
----------- --------- --------- -----------
Loss from
operations $ (8,349) $(11,551) $(41,018) $(48,229)
Provision for
excess and
obsolete
inventories -
product
discontinuation
and lease exit
inventory
charges -- -- 2,045 --
Impairment -- -- 2,971 --
Restructuring 1,690 -- 3,087 --
------ ------- ------- -------
Non-GAAP loss
from operations $ (6,659) $(11,551) $(32,915) $(48,229)
====== ======= ======= =======
Investor Contact:
Priyam Shah
investors@akoyabio.com
Media Contact:
Christine Quern
media@akoyabio.com
(END) Dow Jones Newswires
November 14, 2024 16:00 ET (21:00 GMT)
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。